AUSTIN, Texas , June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference , a virtual event taking
- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas , June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy , PhD, Head of Biotechnology Research at Maxim Group - AUSTIN, Texas , May 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology
- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - AUSTIN, Texas , May 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months – - Target Enrollment is 100 Study Participants - AUSTIN, Texas , May 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Fireside Chat on Wednesday, April 28th at 2:30PM Eastern AUSTIN, Texas , April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B.
AUSTIN, Texas , April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the Sachs 4 th Annual Neuroscience Innovation Forum , a virtual event held on
- 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2 nd Half 2021 - - Initiation of Cognition Maintenance Study On-track for June 2021 - - Cash and cash
AUSTIN, Texas , March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates.
